Mark Toshner, MD

Morphogen-IX Scientific Advisory Board

Mark Toshner undertook a British Heart Foundation Research Training Fellowship in Cambridge in 2007 where he trained in cell and molecular mechanisms of endothelial dysfunction in pulmonary hypertension. He was appointed as a Wellcome/ NIHR Clinical Lecturer in 2010. He is currently a University Lecturer in the University of Cambridge and his group is interested in translational and experimental research in pulmonary vascular diseases. He is currently the Chief-Investigator of the Transform-UK trial, the first investigator-led multicentre trial to involve all 7 specialist centres in the UK. 

Developing BMPs as novel treatments for pulmonary arterial hypertension